Novo Nordisk A S (NVO) EBITDA (2012 - 2016)
Novo Nordisk A S's (NVO) quarterly EBITDA came in at $1.9 billion in Q2 2016, up 2.82% YoY from $1.8 billion in Q3 2015, and up 4.29% on a QoQ basis from $1.8 billion in Q1 2016.
Novo Nordisk A S (NVO) EBITDA (2012 - 2016) Analysis & Trends
Novo Nordisk A S (NVO) has 5 years of EBITDA data on file, last reported at $1.9 billion in Q2 2016.
- Quarterly EBITDA rose 2.82% year-over-year to $1.9 billion in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $7.1 billion (up 1.83% YoY) and the FY2019 annual result came in at $52.5 billion, up 11.08% from the prior year.
- EBITDA grew to $1.9 billion in Q2 2016, from $1.8 billion in the prior quarter.
- In the past five years, EBITDA ranged from a high of $2.1 billion in Q1 2015 to a low of $1.1 billion in Q1 2012.
- A 5-year average of $1.5 billion and a median of $1.5 billion in 2013 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2015 — EBITDA jumped 42.06% — and 2016, when it decreased 13.23%.
- Tracing NVO's EBITDA over 5 years: stood at $1.3 billion in 2012, then increased by 2.05% to $1.3 billion in 2013, then increased by 14.52% to $1.5 billion in 2014, then gained by 5.92% to $1.6 billion in 2015, then advanced by 16.33% to $1.9 billion in 2016.
- The last three EBITDA figures came in at $1.9 billion (Q2 2016), $1.8 billion (Q1 2016), and $1.6 billion (Q4 2015), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2016 | 1.90 Bn |
| Mar 31, 2016 | 1.82 Bn |
| Dec 31, 2015 | 1.63 Bn |
| Sep 30, 2015 | 1.78 Bn |
| Jun 30, 2015 | 1.84 Bn |
| Mar 31, 2015 | 2.09 Bn |
| Dec 31, 2014 | 1.54 Bn |
| Sep 30, 2014 | 1.52 Bn |
| Jun 30, 2014 | 1.61 Bn |
| Mar 31, 2014 | 1.47 Bn |
| Dec 31, 2013 | 1.34 Bn |
| Sep 30, 2013 | 1.42 Bn |
| Jun 30, 2013 | 1.51 Bn |
| Mar 31, 2013 | 1.34 Bn |
| Dec 31, 2012 | 1.32 Bn |
| Sep 30, 2012 | 1.32 Bn |
| Jun 30, 2012 | 1.32 Bn |
| Mar 31, 2012 | 1.13 Bn |